Endothelial extracellular vesicles enhance vascular self-assembly in engineered human cardiac tissues DOI Creative Commons
Karl T. Wagner, Rick Xing Ze Lu, Shira Landau

et al.

Biofabrication, Journal Year: 2024, Volume and Issue: 16(4), P. 045037 - 045037

Published: Sept. 3, 2024

Abstract The fabrication of complex and stable vasculature in engineered cardiac tissues represents a significant hurdle towards building physiologically relevant models the heart. Here, we implemented 3D model vasculogenesis, incorporating endothelial cells (EC), stromal cells, human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CM) fibrin hydrogel. presence CMs disrupted vessel formation tissues, resulting upregulation activation markers altered extracellular vesicle (EV) signaling as determined by proteomic analysis culture supernatant. miRNA sequencing CM- EC-secreted EVs highlighted key EV-miRNAs that were postulated to play differing roles including let-7 family miR-126-3p EC-EVs. In absence CMs, supplementation CM-EVs EC monolayers attenuated migration proliferation resulted shorter more discontinuous self-assembling vessels when applied vascular tissues. contrast, EC-EVs tissue media vascularized mitigated some deleterious effects on self-assembly, enhancing average length continuity tubes formed CMs. Direct transfection validated EC-EV miRNAs let-7b-5p improving maintenance continuous networks. biofabricated microfluidic devices vascularization, illustrating use this approach engineering enhanced, perfusable, myocardium.

Language: Английский

A Comparison of Cellular Uptake Mechanisms, Delivery Efficacy, and Intracellular Fate between Liposomes and Extracellular Vesicles DOI Creative Commons
Timea B. Gandek, Luke van der Koog, Anika Nagelkerke

et al.

Advanced Healthcare Materials, Journal Year: 2023, Volume and Issue: 12(25)

Published: June 29, 2023

Abstract A key aspect for successful drug delivery via lipid‐based nanoparticles is their internalization in target cells. Two prominent examples of such systems are artificial phospholipid‐based carriers, as liposomes, and biological counterparts, the extracellular vesicles (EVs). Despite a wealth literature, it remains unclear which mechanisms precisely orchestrate nanoparticle‐mediated cargo to recipient cells subsequent intracellular fate therapeutic cargo. In this review, involved uptake liposomes EVs by evaluated, also exploring after trafficking. Opportunities highlighted tweak these fates enhance efficacy systems. Overall, literature date shows that both predominantly internalized through classical endocytosis mechanisms, sharing common fate: accumulation inside lysosomes. Studies tackling differences between EVs, with respect cellular uptake, therapy efficacy, remain scarce, despite its importance selection an appropriate system. addition, further exploration functionalization strategies represents important avenue pursue order control fate, thereby improving efficacy.

Language: Английский

Citations

81
Recent advances and clinical translation of liposomal delivery systems in cancer therapy DOI Creative Commons
Jiayi Chen,

Siyuan Hu,

Man Sun

et al.

European Journal of Pharmaceutical Sciences, Journal Year: 2024, Volume and Issue: 193, P. 106688 - 106688

Published: Jan. 1, 2024

The limitations of conventional cancer treatment are driving the emergence and development nanomedicines. Research in liposomal nanomedicine for therapy is rapidly increasing, opening up new horizons treatment. Liposomal nanomedicine, which focuses on targeted drug delivery to improve therapeutic effect while reducing damage normal tissues cells, has great potential field therapy. This review aims clarify advantages systems We describe recent understanding spatiotemporal fate liposomes organism after different routes administration. Meanwhile, various types liposome-based that exert their respective side effects were discussed. Moreover, combination agents with other therapies (such as photodynamic photothermal therapy) demonstrated enhanced tumor-targeting efficiency efficacy. Finally, opportunities challenges faced by liposome nanoformulations entering clinical highlighted.

Language: Английский

Citations

52
Therapeutic potential of RNA-enriched extracellular vesicles: The next generation in RNA delivery via biogenic nanoparticles DOI

Muskan Muskan,

Pevindu Abeysinghe,

Riccardo Cecchin

et al.

Molecular Therapy, Journal Year: 2024, Volume and Issue: 32(9), P. 2939 - 2949

Published: Feb. 27, 2024

Language: Английский

Citations

42
Emerging Strategies for Revascularization: Use of Cell-Derived Extracellular Vesicles and Artificial Nanovesicles in Critical Limb Ischemia DOI Creative Commons

Vijay Murali Ravi Mythili,

Ramya Lakshmi Rajendran, Arun Renganathan

et al.

Bioengineering, Journal Year: 2025, Volume and Issue: 12(1), P. 92 - 92

Published: Jan. 20, 2025

Critical limb ischemia (CLI) poses a substantial and intricate challenge in vascular medicine, necessitating the development of innovative therapeutic strategies to address its multifaceted pathophysiology. Conventional revascularization approaches often fail adequately complexity CLI, identification alternative methodologies. This review explores uncharted territory beyond traditional therapies, focusing on potential two distinct yet interrelated entities: cell-derived extracellular vesicles (EVs) artificial nanovesicles. Cell-derived EVs are small membranous structures naturally released by cells, nanovesicles artificially engineered nanosized vesicles. Both these represent promising avenues for intervention. They act as carriers bioactive cargo, including proteins, nucleic acids, lipids, that can modulate cellular responses associated with ischemic tissue repair angiogenesis. also assesses evolving landscape CLI through unique perspective The spans spectrum from early preclinical investigations latest translational advancements, providing comprehensive overview current state research this emerging field. These groundbreaking vesicle therapies hold immense revolutionizing treatment paradigms.

Language: Английский

Citations

2
Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease DOI
Gabriele De Rubis, Keshav Raj Paudel, Leander Corrie

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2023, Volume and Issue: 397(5), P. 2793 - 2833

Published: Nov. 22, 2023

Language: Английский

Citations

33
Endosomal escape mechanisms of extracellular vesicle-based drug carriers: lessons for lipid nanoparticle design DOI Open Access

Lasse Hagedorn,

David C. Jürgens,

Olivia M. Merkel

et al.

Extracellular Vesicles and Circulating Nucleic Acids, Journal Year: 2024, Volume and Issue: 5(3), P. 344 - 57

Published: July 5, 2024

The rise of biologics and RNA-based therapies challenges the limitations traditional drug treatments. However, these potent new classes therapeutics require effective delivery systems to reach their full potential. Lipid nanoparticles (LNPs) have emerged as a promising solution for RNA delivery, but endosomal entrapment remains critical barrier. In contrast, natural extracellular vesicles (EVs) possess innate mechanisms overcome degradation, demonstrating superior escape (EE) compared conventional LNPs. This mini review explores EE lipid nanoparticle-based offers insights into EV advance LNP design therapeutics. We compare strategies EVs with those used in LNPs highlight contemporary approaches. By understanding EE, we will be able develop more vehicles, enhancing efficacy therapies.

Language: Английский

Citations

12
Exploring the effects of cannabidiol encapsulation in liposomes on their physicochemical properties and biocompatibility DOI Creative Commons
Inga Jurgelāne, Karīna Egle, Andra Grava

et al.

Drug Delivery, Journal Year: 2025, Volume and Issue: 32(1)

Published: Feb. 6, 2025

Cannabidiol (CBD) is recognized for its therapeutic properties in various conditions. However, CBD's limited water solubility and sensitivity to environmental stresses hinder efficacy bioavailability. Encapsulation drug delivery systems, particularly liposomes, offers a promising solution. This study aims prepare CBD-containing liposomes using commercially used lipids distearoyl phosphatidylcholine (DSPC) dipalmitoyl (DPPC), 1,2 distearoyl-sn-glycero-3 phosphoethanolamine-N-[carbonyl-amino(polyethylene glycol)-4300] (ammonium salt) (DSPE-PEG) perform vitro studies - cell viability CBD release. Liposomes were synthesized thin-film hydration method, characterized by Fourier-transform infrared (FT-IR) spectroscopy, dynamic light scattering (DLS), scanning transmission electron microscopy (STEM). DLS analysis revealed that incorporation reduced liposome size 23-53%, depending on the liposomes. efficiency followed order: DPPC (63%) < DSPC (74%) (81%) DSPE-PEG (87%). release profiles indicated released highest amount initially, while exhibited sustained release, achieving 79% over 504 h. In tests showed blank non-cytotoxic. CBD-loaded significantly defined type of containing The inclusion improved encapsulation stability, making more suitable long-term Compared other studies, enhances bioavailability, allowing lower concentrations be directly delivered cells, resulting observable changes viability.

Language: Английский

Citations

2
Investigating the delivery of PD-L1-targeted immunoliposomes in a dynamic cervical cancer-on-a-chip model DOI Creative Commons
Seth‐Frerich Fobian, Mohamadreza Amin, Andrea Sacchetti

et al.

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 379, P. 236 - 250

Published: Jan. 11, 2025

The recent approval of pembrolizumab in recurrent or metastatic cervical cancer warrants further investigations into the usefulness immunotherapies for more durable and less radical interventions. In this study, targeting potential anti-PD-L1-functionalized immunoliposomes was tested a 3D vitro cancer-on-a-chip model. Immunolipsomes were synthesized decorated externally with monovalent anti-PD-L1 Fab' fragments commercially available atezolizumab. Cervical cell lines varying levels PD-L1 expression cultured as spheroids embedded collagen I matrix, treated under flow culture media. Flow cytometry live-cell confocal imaging used to measure interactions uptake untargeted liposomes panel lines. retained specific functionality regardless protein corona formation high serum environments. As such, expressing preferentially internalized environment extracellular matrix present, while low PD-L1-expressing showed no preference either formulation. Importantly, treatments performed monolayer cultures (on plastic) differences between immuno- liposome uptake, including way which endocytosed are trafficked subcellularly. This study demonstrates importance both active passive accumulation strategies achieve nanoparticle targeting. Immunoliposomes remain promising platform development targeted nanotherapies against cancers. However, initial functional tests did not translate directly biological performance should be kept mind future formulations. Furthermore, model developed appeared useful visualizing 3D, live tissue represents cost-effective reproducible studies.

Language: Английский

Citations

1
Cyclic RGD modified dextran-quercetin polymer micelles for targeted therapy of breast cancer DOI
Chao Yang,

Huiling Ma,

Ze Liang

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 308, P. 142272 - 142272

Published: March 19, 2025

Language: Английский

Citations

1
Nanocarriers for targeted drug delivery in the vascular system: focus on endothelium DOI Creative Commons

Xiuxiu Cong,

Zebin Zhang, He Li

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Oct. 12, 2024

Endothelial cells (ECs) are pivotal in maintaining vascular health, regulating hemodynamics, and modulating inflammatory responses. Nanocarriers hold transformative potential for precise drug delivery within the system, particularly targeting ECs therapeutic purposes. However, complex interactions between nanocarriers present significant challenges development clinical translation of nanotherapeutics. This review assesses recent advancements key strategies employing to ECs. It suggested that through physicochemical design surface modifications, can enhance specificity improve internalization efficiency Additionally, we elaborated on applications specifically designed treatment cardiovascular diseases, cancer metastasis, disorders. Despite these advancements, safety concerns, complexity vivo processes, challenge achieving subcellular remain obstacles effective with nanocarriers. A comprehensive understanding endothelial cell biology its interaction is crucial realizing full targeted systems.

Language: Английский

Citations

9